



SPEEDy CELL line development for pandemic response

To accelerate the development and production of biologics
aligned with the EU's "100 Days Mission"



What is SPEEDCELL?

The **SPEEDy CELL line development for pandemic response (SPEEDCELL)** is a four-year EU-cofunded initiative led by HIPRA. It aims to revolutionize how biological products are developed and produced, particularly in the context of pandemics and public health emergencies, transforming current drawbacks in bioproduction processes into **a faster, more scalable, and cost-efficient platform.**

The project aligns with **European strategies to strengthen health security and address systemic medicine shortages**, particularly in the context of health crises and pandemics.





What is the main objective?

To accelerate the development and production of vaccines and other biotech products, enabling a swift response to health emergencies, **aligned with the EU's "100 Days Mission"**.

What is our mission?

SPEEDCELL's mission is to boost Europe's ability to respond to health emergencies by streamlining cell line development and manufacturing. By fostering innovation and flexibility, the project enables the rapid production of affordable, high-quality biologics, **in line with HERA's goals** for improved access to essential medical countermeasures.



Who are we?

HIPRA is a globally recognized biotechnological pharmaceutical company with more than 50 years of experience dedicated to advancing human and animal health through innovative solutions in prevention and treatment.

With a strong commitment to research and development and a state-of-the-art facilities, HIPRA continuously strives to address the evolving needs of global health and improve the well-being of people and animals worldwide aligned with the One Health vision.

Website: www.speedcellproject.eu

Social media: <https://www.linkedin.com/company/speedcell-project-eu/>

Contact: **HIPRA Image & Communications department** - press@hipra.com



**Co-funded by
the European Union**

Co-funded by the European Union under grant agreement N° 101136439. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union (EU) or European Health and Digital Executive Agency (HaDEA). Neither the EU nor HaDEA can be held responsible for them.





Co-funded by
the European Union